Timothy Eugene Sullivan - 08 Jun 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Financial Officer
Issuer ticker: APLS
Reported as of: 08 Jun 2021
Net transaction value: +$399,996
SEC form: 4
Accepted by SEC: 09 Jun 2021, 16:06:00 UTC
Next SEC filing: 25 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ David Watson as attorney-in-fact for Timothy Sullivan

Key filing fact

Timothy Eugene Sullivan filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 09 Jun 2021.

Key facts

This page summarizes Timothy Eugene Sullivan's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2021, 16:06.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$399,996.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Options Exercise

Transaction value: $399,996
Shares: +39,880
Change %: +116%
Price: $10.03
Shares after: 74,141
Date: 08 Jun 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -39,880
Change %: -10%
Price: $0.000000
Shares after: 358,619
Date: 08 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,880
Exercise price: $10.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on October 18, 2017 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.